Good Quality 66.7% 5-year Overall Survival in Terminal Lung Cancer Patients Treated With Mifepristone
The likelihood of this type of response occurring by chance is extremely low. It is hoped that this report will encourage oncologists, scientists, and clinicians to further investigate the use of SPRMs in a larger cohort of patients with stage IV lung cancer, and potentially in those with less advanced disease.
Authors
- Jerome H. Check
- C. Wilson
- Diane Check
Institutions
- Cooper Medical School of Rowan University (US)
- Cooper Institute for Reproductive Hormonal Disorders (US)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-11-29
- DOI
- https://doi.org/10.21873/anticanres.17911
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52